Difference between revisions of "Fondaparinux (Arixtra)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information") |
||
(16 intermediate revisions by 4 users not shown) | |||
Line 1: | Line 1: | ||
==General information== | ==General information== | ||
− | Class/mechanism: Selectively binds to antithrombin III (AT-III) and augments its activity to specifically inhibit activated Factor Xa. | + | Class/mechanism: Selectively binds to antithrombin III (AT-III) and augments its activity to specifically inhibit activated Factor Xa. The risk of developing thrombus is reduced via inhibition of thrombin, which converts fibrinogen to fibrin in the coagulation cascade.<ref name="insert">[[:File:Fondaparinux.pdf | Fondaparinux (Arixtra) package insert (locally hosted backup)]]</ref> |
<br>Route: SC | <br>Route: SC | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
− | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref> |
==Patient drug information== | ==Patient drug information== | ||
− | *[ | + | *[[:File:Fondaparinux.pdf | Fondaparinux (Arixtra) package insert (locally hosted backup)]]<ref name="insert"></ref> |
*[http://www.uptodate.com/contents/fondaparinux-patient-drug-information Fondaparinux (Arixtra) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/fondaparinux-patient-drug-information Fondaparinux (Arixtra) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/fondaparinux-patient-drug-information Fondaparinux (Arixtra) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/fondaparinux-patient-drug-information Fondaparinux (Arixtra) patient drug information (UpToDate)]</ref> | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
− | *12 | + | *2001-12-07: Initial approval: prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism in patients undergoing hip fracture surgery; patients undergoing hip replacement surgery; or patients undergoing knee replacement surgery. |
− | + | ==History of changes in EMA indication== | |
− | + | *2002-03-20: Initial authorization | |
− | |||
− | |||
==Also known as== | ==Also known as== | ||
− | + | *'''Brand names:''' Arixtra, Quixidar | |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
==References== | ==References== | ||
<references/> | <references/> | ||
+ | |||
+ | [[Category:Drugs]] | ||
+ | [[Category:Subcutaneous medications]] | ||
+ | [[Category:Anticoagulants]] | ||
+ | |||
+ | [[Category:Heparin-induced thrombocytopenia medications]] | ||
+ | [[Category:Venous thromboembolism medications]] | ||
+ | |||
+ | [[Category:FDA approved in 2001]] | ||
+ | [[Category:EMA approved in 2002]] |
Latest revision as of 01:06, 29 June 2024
General information
Class/mechanism: Selectively binds to antithrombin III (AT-III) and augments its activity to specifically inhibit activated Factor Xa. The risk of developing thrombus is reduced via inhibition of thrombin, which converts fibrinogen to fibrin in the coagulation cascade.[1]
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]
Patient drug information
- Fondaparinux (Arixtra) package insert (locally hosted backup)[1]
- Fondaparinux (Arixtra) patient drug information (UpToDate)[2]
History of changes in FDA indication
- 2001-12-07: Initial approval: prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism in patients undergoing hip fracture surgery; patients undergoing hip replacement surgery; or patients undergoing knee replacement surgery.
History of changes in EMA indication
- 2002-03-20: Initial authorization
Also known as
- Brand names: Arixtra, Quixidar